Therapeutic treatments for late-onset Alzheimer's disease (LOAD) are hindered by an incomplete 27 understanding of the temporal molecular changes that lead to disease onset and progression. Here, we 28 evaluate the ability of manifold learning to develop a molecular model for the unobserved temporal 29 disease progression from RNA-Seq data collected from human postmortem brain samples collected 30 within the ROS/MAP and Mayo Clinic RNA-Seq studies of the AMP-AD consortium. This approach 31 defines a cross-sectional ordering across samples based on their relative similarity in RNA-Seq profiles 32 and uses this information to define an estimate of molecular disease stage -or disease progression 33 pseudotime -for each sample. This transcriptional estimate of disease progression is strongly concordant 34 with burden of tau pathology (Braak score, P = 1.0x10 -5 ), amyloid pathology (CERAD score, P = 1.8x10 -35 5 ), and cognitive diagnosis (P = 3.5x10 -7 ) of LOAD. Further, the disease progression estimate 36 recapitulates known changes in cell type abundance and impact of genes that harbor known AD risk loci. 37
Introduction 46
Late-onset Alzheimer's disease (LOAD) is a devastating illness with no effective disease modifying 47 therapy, owing to a 99.6% failure of clinical trials 1 . There is a growing consensus that the most effective 48 treatments will intervene early in disease progression and halt disease pathophysiological processes prior 49 to conversion to LOAD 2 . In addition, there is increasing recognition that LOAD may in fact be a 50 spectrum of related diseases that have similar clinical and neuropathological manifestations 3, 4 . Devising 51 successful therapeutic strategies will likely require targeting potentially diverse early-stage disease 52 processes that occur prior to a high burden of neuropathology or cognitive impairment. 53 54 Current approaches to identify AD affected individuals include in vivo measures of the pathological 55 hallmarks of disease -amyloid, tau, and neurodegeneration -via CSF biomarkers for amyloid and tau 5 , 56 positron emission tomography for amyloid and tau (PET) 6 , and structural and functional MRI of 57 neurodegeneration. Cognitive assessments are used to estimate disease burden 7 , although measurable 58 cognitive impairment generally indicates a sustained burden of neuropathology and advanced 59 neurodegeneration. Based on biomarker studies of AD, by the time cognitive decline becomes detectable, 60
neuropathological changes of AD have already occurred, first in Aß and subsequently in tau related 61 measures 8 and therefore cannot be used to select patients for early disease stage studies. Furthermore, 62 while these measures of disease progression capture the overall increase in burden of pathology and 63 cognitive decline, they do not necessarily identify the dysfunctional molecular mechanisms that lead to 64 neuropathology and cognitive decline. There are likely many independent patient specific molecular 65 pathways present at an early stage in disease that then contribute to later stage disease progression 9, 10 . 66
This motivates the need to identify these early stage molecular mechanisms driving disease progression. 67
68
The Accelerating Medicines Project for Alzheimer's Disease (AMP-AD) consortia have generated 69 genome-wide transcriptomics of post-mortem brain tissue from patients across a broad range of 70
Alzheimer's disease neuropathological progression -including individuals with various stages of AD 71 neuropathology and those who lack AD neuropathology, but who may in face harbor early stage disease 72 molecular processes. We therefore sought to chart the molecular progression of the disease as reflected in 73 the aggregate behavior of the CNS transcriptome across these individuals. While standard approaches 74 such as differential expression or coexpression analyses have proven informative [11] [12] [13] [14] [15] , these analyses do 75 not infer the relative stage of disease progression or identify distinct disease subtypes. Here we propose 76 an approach to analyze population level RNA-seq data from post-mortem brain tissue to learn a tree 77 structured progression (Figure 1) that represents distinct sub-types of disease and the relative progression 78 of disease across patients. With this approach, we identify potentially generalizable trajectories of LOAD 79 across heterogeneous patient populations at all stages of disease. Furthermore, we characterize molecular 80 pathways that define disease stages -a potential source of new biomarkers and therapeutic interventions 81 for early-stage disease processes along multiple different disease trajectories. 82
83
To learn the molecular disease staging and neuropathologic progression tree we use a manifold learning 84 method 16 . Manifold learning refers to a group of algorithms that aim to recover the low dimensional 85 subspace underlying a high dimensional dataset. Previous authors use manifold learning to estimate 86 disease progression from neuroimaging data 17 and to study lineage commitment of cells during 87 differentiation from single cell RNA-seq (scRNA-seq) 18-21 . To our knowledge, manifold learning has not 88 been used to estimate disease progression and/or disease stages from bulk RNA-seq data derived from 89 post-mortem tissue. Henceforth, we refer to manifold learning, lineage inference interchangeably in 90 reference to the construction of the inference of a neuropathologic progression tree. We demonstrate that 91 these tools can estimate the disease staging and progression tree (Figure 2 ) from bulk RNA-Seq data 92 collected from post-mortem brain tissues in a case/control cohort. Moreover, these trees show clear 93 LOAD staging, enable the study of cell type specific effects of LOAD, and allow the identification of 94 genetic factors driving disease progression. 95
Results 96

Unsupervised manifold learning distinguishes pathologically defined LOAD from control 97
We first quantify the bulk RNA-Seq data from the ROS/MAP and Mayo Clinic cohorts into gene counts 98 and remove any batch effects introduced due to sequencing runs using standard count normalization (see 99 Methods). The data from the ROS/MAP cohort is sampled from the dorsolateral prefrontal cortex 100 (DLPFC), and the data from the Mayo Clinic cohort is sampled from the temporal cortex (TCX). The full 101 pipeline we use for RNA-Seq data generation and quality control was recently reported 22 . The entire 102 transcriptome comprises many genes which do not have measurable expression or vary across 103 case/control samples, which we remove in order to reduce the noise in manifold learning 19 . To do this, we 104 first perform differential expression analysis between case/control samples separately for each study and 105 retain genes that reach an FDR of 0.10. To test if this biased the disease lineage inference, we also 106 perform manifold learning using only genes with high variance across samples, and we see a strong 107 concordance with disease lineages inferred with differentially expressed genes ( Figure S4) . We infer the 108 disease lineage for each brain region on this subset of retained genes (Figure 2A-B ). Furthermore, we 109 observe strong evidence of sex heterogeneity when performing the manifold learning approach, and find 110 that the manifolds inferred for female only samples are much more robust than for male samples. This 111 matches previous observations concerning disease specific sex heterogeneity 22 . We only show results for 112 manifolds inferred on female samples. 113
114
We first visualize the clinical diagnosis of the samples on the inferred disease staging tree to verify that 115 there is indeed separation of AD patients across the tree. To determine if inferred tree structure is an 116 accurate model of disease progression, we introduce the notion of disease pseudotime which is the 117 geodesic distance along the tree from an inferred initial point to the point of interest as a quantitative 118 linear measure of LOAD stage. We scale this estimated disease pseudotime to lie in the range ሾ 0 , 1 ሿ to 119 make the effects comparable between the two studies (and brain regions). We show that for LOAD cases 120 compared to controls there is a significant association (P = 0.02 in Mayo and P= 2.0x10 -6 in ROS/MAP, 121 logistic regression) between the estimated pseudotime and AD case/control status ( Figure 2C) . 122
123
We test whether genes in loci that have been implicated in genome wide association studies of LOAD are 124 associated with inferred disease pseudotime. We use the highest ranked LOAD GWAS genes (60 genes 125 in total) 23 , Table S1 , and compute the correlation between their expression and inferred pseudotime 126 ( Figure 2D) . When compared to the background of all genes, we see that there is a significant increase in 127 positive correlation with disease pseudotime for implicated LOAD GWAS genes (P-value: 7.3x10 -5 in 128
Mayo and 5.6x10 -3 in ROS/MAP). Furthermore, this does not appear to be driven by a small subset of 129 outlier genes, but by the majority of the distribution of LOAD GWAS genes. The fact that AD GWAS 130 loci genes have expression associations with pseudotime likely implies that the AD risk variants at these 131 are also eQTL as previously shown 24-27 and/or are members of co-expression networks that are 132 differentially expressed in AD 13, 28 . 133
134
To further explore the relationship between inferred disease stage and LOAD, we test for its association 135 with neuropathological and clinical measures of LOAD severity, namely: i) Braak score, ii) CERAD 136 score, and iii) cognitive diagnosis. The ROSMAP study has numeric scores for these categories available 137
as covariates for each sample. Braak is a semi-quantitative measure that increases with tau pathology 29 138 and CERAD is a semi-quantitative measure of density of neuritic plaques 30 . We overlay these scores on 139 the inferred manifold for the DLPFC brain region ( Figure 3A) . We observe a progressive increase in tau, 140 amyloid, and cognitive burden as we traverse the inferred disease manifold ( Figure 3A) . This is further 141 quantified by characterizing the relationship between branches of the inferred manifold and Braak, 142 CERAD, and cognitive diagnosis ( Figure 3B ). We observe significant associations between pseudotime 143 and Braak score (P=1.0x10 -5 ), CERAD score (P=1.8x10 -5 ), and cognitive diagnosis (P=3.5x10 -7 ). 144
Inferred staging recapitulates known biology of AD 145
To demonstrate that the inferred disease pseudotime recapitulates known biology of LOAD, we test for 146 association between inferred disease stage and both the cellular response to disease and the genetics of the 147 disease. A prominent hypothesis in AD is that the effects of the disease vary across different brain cell 148 types, specifically neurons and glial subtypes. Current understanding of the cell biology of the disease 149 implicates progressive neuronal loss and increase in gliosis 31 . To test if the inferred pseudotime aligns 150 with existing cell type specific hypotheses regarding AD, we first selected from the genes used in lineage 151 construction the marker genes for four key cell types: neurons, astrocytes, microglia, and 152 oligodendrocytes based on a previously published brain cell atlas 32 (Table S2) . We then calculate the 153 normalized mean expression for the marker genes of each cell type and fitted a linear model to the mean 154 expression with disease pseudotime as the dependent variable. We find that, in both studies, the cell 155 specific marker gene levels show a statistically significant linear dependence on pseudotime (Table S3) . 156
Fitted effects recapitulate known neuropathologic changes which occur in AD, namely: i) a reduction in 157 the neuronal populations as AD progresses, and ii) an increase in expression associated with activation of 158 microglia, astrocytes, and oligodendrocytes as AD progresses (Figure S5) . 159 Lineage inference of LOAD transcriptomes provides a quantitative measure of disease progression for 168 genetic associate testing, and the significantly greater correlation between pseudotime and gene 169 expression for known LOAD risk genes (Figure 2D ) suggests that the observed differences in disease 170 trajectories are influenced by genetic factors. To test this hypothesis, we perform single variant analysis 171 using whole-genome sequencing data for 305 patients from the ROS/MAP and 131 patients from the 172 Mayo cohort. Despite the limited sample size, resulting in lack of statistical power to discover genome-173 wide significant associations, multiple variants reach a genome-wide suggestive threshold of p < 1x10 -5 174 (Table S4 ). We do not see evidence of population stratification in the analysis (Figure S8-S9) . Notably, 175
the most significant association with pseudotime for the ROS/MAP cohort is observed at the PTPRD 176 locus (rs7870388, p = 1.31 x 10 -6 ) ( Figure S10 , Table S4 ). The PTRPD locus is associated with the 177 susceptibility to neurofibrillary tangle independent of amyloid deposition in the ROS/MAP cohort 33 . For 178 the Mayo Clinic cohort, known LOAD variants in the APOE (rs6857, p = 9.18 x 10 -6 ) and BIN1 179 (rs62158731, p= 4.68 x 10 -5 ) loci overlap with variants associated with inferred disease stage (Figure 180 S10, Table S4 ) 34 . When comparing our association results for inferred disease stage with summary 181 statistics from a large-scale case-control approach, we identify multiple variants which have been 182 previously associated with LOAD in the IGAP cohort (Table S5 ). Furthermore, we identify several 183 potential novel candidate genes associated with inferred disease stage (ADAMTS14, IL7, MAN2B1) linked 184 to immune and lysosomal storage function (Figure S10 , Table S4 ). IL-7 has been proposed as an 185 inflammatory biomarker for LOAD that correlates with disease outcome and severity 35 . ADAMTS14 is 186 part of a locus that has been previously linked with Alzheimer susceptibility and plays an important role 187 in the regulation of immune function via TGF-beta signaling. 188
New disease insights identified from inferred disease lineages 189
Another important direction of study in the field of Alzheimer's is the identification of disease subtypes, 190 which has so far predominantly been done using imaging data 36 . The branches of the inferred disease trees 191 provide a new transcriptomic-based approach to identify disease subtypes. In both brain regions and in 192 two separate cohorts, there were two distinct early-lineage branches corresponding to predominantly 193 control samples, which we interpret as different initial paths towards the disease. Similarly, both brain 194 regions feature several distinct branches with predominantly LOAD samples (Figure 2A-B) . 195 196 Branch-specific differential expression patterns. To study the genes and pathways specific to each branch, 197
we perform a branch-specific differential expression analysis with an ANOVA model using the branches 198 with the highest proportion of controls as the reference branch for DLPFC (Table S6 ) and TCX ( Table  199 S7). We see many genes are differentially expressed between the control branch and branches that are 200 enriched in the affected individuals (Table S8 ). Next, we performed an enrichment analysis on each of 201 these differentially expressed gene sets with the enrichR 37 package for Gene Ontology 38 annotations 202 (Methods). The results of this enrichment analysis for DLPFC and TCX tissues (Table S9-S10). Only 203 gene sets with significant enrichment are shown (FDR adjusted p-value < 0.05). Overall, we see a pattern 204 of loss of expression of basic cell biology mechanisms in early-stage branches including RNA splicing, 205 mitochondria function, protein transport, and DNA repair. Late-stage branches were characterized by 206 increased immune response (e.g. TGFb/WNT signaling) and apoptotic activity ( Table 1) . 207 208 While studying the different branches in the two brain regions, we observe a branch (branch 5) that 209 corresponds to a group of predominantly neuropathological control samples from the Mayo RNA-seq 210 cohort that were in close proximity to a branch with predominantly LOAD samples (branch 4) on the 211 inferred disease lineage ( Figure 4A) . However, most of the samples on branch 5 are neuropathological 212 controls as defined by the Mayo diagnostic criteria. We bi-cluster the mean expression of genes in each 213 branch and the branches themselves (Methods). This clustering analysis ( Figure 4B) shows that the 214 closest branch to this potentially disease resistant branch contains the highest proportion of AD samples. 215
While the stage proximity implies some transcriptomic similarity between these controls and nearby 216 cases, we also see a secondary cluster of genes with increased expression in the resistant state while 217
having reduced expression in all other states. We perform an enrichment analysis on this set of genes and 218 find significant GO terms corresponding to: protein transport (GO:0015031), regulation of mRNA 219 splicing, via spliceosome (GO:0048024), negative regulation of apoptotic process (GO:0043066), and 220 regulation of amyloid-beta clearance (GO:1900221) (Cluster4 , Table S11 ). It is possible that these 221 potentially disease resistant individuals have compensatory mechanisms which suppress the hallmarks of 222 disease despite sharing gene expression patterns with pathologically affected individuals. These 223 observations are preliminary, and would need to be replicated in a second cohort to verify the existence of 224 a disease resistant gene expression signature. 225
Discussion 226
Here we proposed a novel approach to infer the Alzheimer's disease severity and disease subtypes in an 227 unsupervised manner from post-mortem bulk RNA-seq data that gets directly at the challenge of 228 identifying the temporal progression of disease in the disease resident tissue. Our strategy utilized a 229 manifold learning approach to infer a disease progression tree from cross-sectionally collected patient 230 samples from two different brain regions. The underlying assumption of our approach is that the inferred 231 disease progression from cross sectional samples serves as a proxy for the unobserved progression of the 232 disease across subtypes of LOAD. We validated this hypothesis through comparisons with 233 neuropathological measures of disease stage severity and against known cell type specific effects caused 234 by the disease. Furthermore, this approach provides clues to better understanding the molecular 235 heterogeneity of disease by identifying specific pathways that are dysregulated in subsets of patients at 236 different disease stages. This opens up the possibility of better patient stratification and precision 237 medicine. 238
239
We observed that different biological processes vary as a function of inferred disease stage, and that 240 early-stage disease processes potentially include RNA-splicing, mitochondrial function, and protein 241 transport -implicating multiple basic cell biology mechanisms as potential early stage disease processes 242 for further study in relevant model systems. Additionally, the manifold learning method identified 6 243 potential subtypes of LOAD from RNA-seq (i.e. branches) suggesting the LOAD populations should be 244 stratified by better biomarkers with tailored treatment strategies. To identify and test these stratifications 245 future studies should focus on longitudinal cohorts of patients with rich molecular and imaging data to be 246 able to identify biomarkers that can accurately and precisely stratify patients into the underlying 247 molecular subtypes in terms of the molecular characteristics of their transcriptome and different relative 248 stages of disease. Furthermore, we observe a potential disease resistant sub-type of patients. This disease 249 resistance should be tested in disease model systems, to identify if neuropathological readouts can be 250 modified by altering the function of the pathways identified in our analysis (e.g. APP processing, RNA 251 splicing, apoptosis, protein trafficking). While this preliminary observation needs to be validated in 252 another cohort, it has the potential to be a novel source of hypotheses concerning new therapeutic 253 development. Specifically, for constructing better combination therapy hypotheses that may confer 254 neuroprotection, even in patients that are mildly affected by disease. 255
256
LOAD is a complex and heterogeneous disease encompassing a broad spectrum of clinical symptoms. 257
Disease progression can vary widely between patients leading to different rates of cognitive decline. 258
Several lines of evidence suggest that these differences in progression are modified by multiple genetic 259 factors affecting the transition from one pathological state to another 39,40 . However, it has remained 260 difficult to assess the role of genetic variants affecting disease trajectories by case-control approaches 261 alone. Here, we showed that our novel expression trait pseudotime might be used as a molecular 262 phenotype to identify known and novel AD loci associated with different disease progression states across 263 AD patients. Despite a limited sample size, we identified previously associated AD candidate loci in the 264 ROSMAP (PTPRD) and Mayo (BIN1, APOE) cohorts with suggestive significance (p < 1 x 10 -5 ). 265
Variants in PTPRPD have been associated with the susceptibility to neurofibrillary tangles, independent 266 of amyloid burden. This is in line with the results from the differential gene expression analysis of 267 pseudotime branches showing an enrichment of molecular pathways implicated in TAU pathology. 268
Furthermore, our analysis revealed several novel loci linked to immune function (ADAMTS14, IL7) and 269 neurotransmitter signaling (CHRM2, CHRM3) processes associated with disease pseudotime (Table S4) 
. 270
Future studies will be needed to replicate these findings in independent cohorts of LOAD and validate the 271 role of candidate genes in LOAD related disease progression by first identifying peripheral biomarkers 272 that correspond to this molecular definition of disease stage, and then testing for GWAS association with 273 that disease stage. Subsequent results can improve functional interpretation by linking candidate genes 274 with ordered pathological processes. 275
276
Methods 277
RNA sequencing 278
The details of the sample collections, postmortem sample characteristics, the tissue and RNA 279 preparations, the library preparations and sequencing technology and parameters, and sample quality 280 control filters are provided in previously published work 41, 42 . Furthermore, details of the bioinformatic 281 pipeline used to generate count level data has been previously described 22 . Briefly, reads were aligned to 282 the GENCODE24 (GRCh38) reference genome with STAR 43 , and gene counts generated using the 283 HTSeq algorithm 44 . Genes that had more than one counts per million total reads total reads in at least 284 50% of samples in each tissue and diagnosis category were used for further analysis. 285 286
Differential Expression analysis on Mayo and ROS/MAP cohorts 287
For gene filtering we used false discovery rate of 0.05 from the previously published differential 
Manifold learning for LOAD 299
Manifold learning refers to a group of machine learning algorithms that recover a low dimensional 300 subspace underlying a high dimensional dataset. Manifold learning approaches are typically used in 301 datasets or applications where data samples lie on an underlying low dimensional latent space (e.g. a tree, 302 a line, a curved plane). The low dimensional space is learned via a projection from the high dimensional 303
space of the observed data (e.g. RNA-seq profiles across hundreds of patient samples) down to a low 304 dimensional space with suitable regularization constraints to enforce smoothness and the structural 305 constraints of the low dimensional space. (Figure 1A) . Due to the necessary assumption of an underlying 306 latent subspace, manifold learning is commonly used in applications where it is known that the observed 307 data is obtained from a progression of some kind; e.g., i) to infer the temporal ordering of a sequence of 308 images, or ii) to infer the approximate lineage of cells in a differentiation trajectory using single cell 309 RNA-Seq data (Figure 1B-C) . 310
311
Here, we repurpose methods originally developed for learning cell lineage using scRNA-Seq data, to infer 312 the staging of Alzheimer's disease (AD) using bulk RNA-Seq data from post-mortem brain samples with 313 known AD diagnosis status. Since bulk RNA-Seq has many of the same sampling and distributional 314
properties as scRNA-Seq, we observe that scRNA-Seq methods are applicable with no additional 315 modifications. As such, we use the DDRTree manifold learning approach available in the Monocle 2 R 316 package 19 . However, we also show that the estimated staging of disease is quite similar across some of 317 the other common methods used for scRNA-Seq lineage estimation (Figures S1-S3) . 318
319
The RNA-Seq data used in this study was generated from post-mortem brain homogenate samples, and 320 obtained from two separate studies that are a part of the Accelerating Medicines Partnership in 321 individuals with mild cognitive impairment. Furthermore, the results presented in the main paper are 329 from female samples only, as we observed significant sex differences in the transcriptomic data consistent 330 with current knowledge of sex differences in LOAD 50,51 , making a common analysis of both sexes 331 untenable. 332 333
Manifold learning using Discriminative Dimensionality Reduction Tree (DDRTree) 334
DDRTree is a manifold learning algorithm that infers a smooth low dimensional manifold by an approach 335 called reverse graph embedding. Briefly, the algorithm simultaneously learns a non-linear projection to a 336 latent space where the points lie on a spanning tree. A reverse embedding is also simultaneously learned 337 from the latent space to the high dimensional data. Mathematically, the DDRTree algorithm can be posed 338 as the following optimization problem: 339 term of the optimization problem is responsible for learning a low dimensional representation of the data 346 such that an inverse mapping exists to the high dimensional data points, the second term learns the tree 347 structure of the points and the third term learns a soft clustering for the latent dimension points as well as 348 the centers of the clusters. Despite the non-convexity of the problem, each individual optimization 349 variable can be solved for efficiently using alternative minimization as described previously 52 
Branch assignment and pseudotime calculation for samples 357
Branch assignment and pseudotime calculation was also performed using the Monocle package using 358 techniques described previously 19 . Briefly, pseudotime is calculated by first identifying a root point on 359 one of the two ends of the maximum diameter path in the tree. Then the pseudotime of each point is 360 calculated by projecting it to its closest point on the spanning tree and calculating the geodesic distance to 361 the root point. Assigning samples to branches is done by first identifying the branches of the spanning 362 tree and then assigning samples to the branch on which their projection to the spanning tree lies on. 363
364
Association of pseudotime with AD status, hallmarks of Alzheimer's disease, and cognitive diagnosis 365
We test for association between disease pseudotime and AD case or control status with logistic regression 366 with AD case or control status as the outcome and inferred pseudotime as the dependent variable in both 367 the Mayo and ROS/MAP studies. We test for association between pseudotime and hallmarks of disease 368 in the ROS/MAP studies for both Braak (measure of tau pathology) score and CERAD score (measure of 369 amyloid pathology) with an ordinal logistic regression model, with the neuropath score as the ordered 370 outcome, and pseudotime as the dependent variable. Finally, we test for association between disease 371 pseudotime and cognitive diagnosis for the following ordered clinical diagnoses of no cognitive 372 impairment, mild cognitive impairment, and probable Alzheimer's disease with an ordinal logistic 373 regression model. All code for running these association tests is available https://github.com/Sage-374 Bionetworks/AMPAD_Lineage/blob/paper_rewrites_1/paper_figures.Rmd. 375
376
Inferring cell type specific expression patterns given marker gene expression as a function of pseudotime 377
List of marker genes for different major cell types in the brain was curated from a previously published 378 brain cell expression signature study 32 . The marker gene list was then pruned to include only genes that 379 were included in lineage construction. Each gene's expression as a function of pseudotime was then 380 obtained by smoothing using a smoothing spline of degree of freedom = 3 and normalized to lie in [0,1]. 381
The smoothing was done to remove the effects of technical noise introduced due to RNA-Seq and the 382 normalization was done since the absolute expression levels of genes might be very different from each 383 other. The smoothed and normalized expression of marker genes for each category were then averaged to 384 obtain the average marker gene expression as a function of pseudotime. A linear model was used to test 385 for association between average expression of a given cell type expression signature and pseudotime. 386 387
Association between GWAS loci and correlation with pseudotime 388
To test for association between pseudotime and LOAD GWAS genes, we computed the Spearman's 389 correlation between each gene's expression and pseudotime in the Mayo and ROS/MAP studies. Next, 390 we identified a set of genes implicated in AD GWAS loci in the International Genetics of Alzheimer's 391 Project (IGAP) 23 . We treated the set of genes described in Tables 1-3 of that study as high quality 392
candidate AD GWAS genes 23 . We test for a difference between the correlation with pseudotime of 393 background of all other genes and the IGAP AD genes using a linear model, and see a significant increase 394 in correlation between gene expression and pseudotime in both the Mayo and ROS/MAP study for AD 395 GWAS genes. 396 397
Branch specific differential expression analysis 398
We perform a state specific differential expression analysis using a one-way ANOVA model in both the 399 Mayo and ROS/MAP studies. The branch with the highest proportion of AD controls is defined as the 400 reference branch for all analyses. We use Tukey's honest significant difference method to compute P- 
Estimating branch specific gene expression signatures 409
Branch specific expression signature was obtained by first calculating the average normalized expression 410 for all genes in each state/branch. This was followed by performing a bi-clustering using the pheatmap 411 package in R which uses hierarchical clustering on both samples and genes. We also used the pheatmap 412 package to visualize the state specific expression signatures. 413 414
Gene set enrichment analyses 415
For each branch specific differential expression gene set (DEGs) in both Mayo and ROS/MAP we 416 perform a gene set enrichment analysis against Gene Ontology pathways using the enrichR R package. 417
Only pathways with FDR < 0.05 are reported. Illumina HiSeq X sequencer using 2 x 150bp cycles. Paired-end reads were aligned to the GRCh37 432 
Single variant association with pseudotime in two independent cohorts 440
Likelihood ratio tests within a linear regression framework were used to model the relationship between 441 the quantitative expression trait pseudotime and genetic variants in 436 AD cases. Genome-wide genetic 442 association analysis was performed for 305 female patients in the ROS/MAP cohort and 131 female 443 patients in the Mayo cohort for which both genotyping and post-mortem RNA-seq data was available. An 444 efficient mixed model approach, implemented in the EMMAX software suite, was used to account for 445 potential biases and cryptic relatedness among individuals 55 . Only variants with MAF > 0.05, genotyping 446 call rates > 95%, minimum sequencing depth of 20 reads and Hardy-Weinberg equilibrium p >10 -4 were 447 considered for analysis. Quantile-quantile plots (Figure S8-S9) for the test statistics showed no 448 significant derivation between expected and observed p-values, highlighting that there is no consistent 449 differences across cases and controls except for the small number of significantly associated variants. 450 Furthermore, the genomic inflation factor (lambda) was determined to be 0.99 for the Mayo and 0.98 for 451 the ROS/MAP single variant association tests. This highlights that potential confounding factors, such as 452 population stratification have been adequately controlled. indicating a strong disease-like transcriptomic phenotype, yet most samples in the group did not have 625 pathologically diagnosed AD (Figure 2A ). We hypothesize this group represents a disease resistant state 626 to the disease. B) Biclustering results of average expression from each disease state, with increased 627 expression of a gene cluster unique to State 5. 628
Disease Resistant State
